hepat
b
viru
hbv
infect
chronic
difficult
cure
clinic
treatment
continu
major
public
health
problem
china
hepat
b
viru
surfac
antigen
hbsag
carrier
rate
account
percent
popul
one
third
worldwid
carrier
hbv
prototyp
hepadnavirida
famili
small
envelop
hepatotrop
dna
virus
infect
liver
human
infect
viru
result
seri
clinic
symptom
rang
minor
flulik
symptom
acut
fulmin
chronic
hepat
liver
cirrhosi
liver
carcinoma
even
result
death
hbv
estim
respons
death
year
number
drug
avail
treat
hepat
b
viral
infect
includ
interferon
ifn
thymosin
famciclovir
fcv
adefovir
adv
lamivudin
lam
et
al
howev
none
therapi
complet
safe
effect
clinic
explor
promis
antivir
agent
like
nucleosid
analogu
hamper
signific
side
effect
especi
develop
resist
virus
therefor
crucial
explor
safer
efficaci
less
expens
antihbv
agent
polyoxometal
pom
inorgan
clusterlik
complex
constitut
oxid
anion
transit
metal
cation
complex
versatil
use
catalyt
process
magnet
materi
nanotechnolog
medic
procedur
sever
pom
especi
use
medicin
chemistri
serv
new
kind
inorgan
medicin
candid
possess
antivir
antitumor
antibiot
activ
extrem
small
sub
nm
dimens
exhibit
low
toxic
stabl
biolog
media
liabl
clear
renal
system
engin
variou
applic
especi
antivir
agent
pom
wide
research
recent
year
proven
activ
wide
rang
virus
includ
rna
virus
dna
virus
human
immunodefici
rna
viru
hiv
sever
acut
respiratori
syndrom
rna
viru
sar
influenza
rna
viru
herp
simplex
dna
viru
hsv
mechan
antivir
action
may
occur
prevent
viral
adsorpt
penetr
inhibit
activ
retroviridas
advantag
pom
antivir
activ
inspir
us
find
effect
antihbv
drug
candid
field
among
variou
pom
keggintyp
niobiumsubstitutedheteropolytungst
interest
us
broadspectrum
antivir
activ
especi
antihiv
compound
synthes
purifi
character
thereaft
toxic
antivir
activ
hepat
b
viru
investig
hepg
result
indic
compound
exhibit
high
activ
hbv
low
toxic
although
pom
studi
mani
year
report
relev
pharmacokinet
studi
rel
rare
howev
paper
detail
publish
investig
pom
pharmacokinet
ni
et
al
atom
emiss
spectrometri
method
determin
concentr
pom
rat
alreadi
describ
group
sinc
limit
method
insensit
less
select
detect
limit
induct
coupl
plasmamass
spectrometri
icpm
method
sensit
select
first
appli
determin
concentr
w
plasma
urin
fece
bile
organ
sampl
find
studi
would
use
evalu
potenti
medicin
applic
compound
perfect
complet
pharmacokinet
pom
compound
patent
patent
synthes
school
public
health
jilin
univers
china
use
procedur
describ
literatur
compound
character
ultraviolet
spectrometri
infrar
spectrometri
nuclear
magnet
reson
molecular
mass
compound
dalton
w
standard
solut
naoh
obtain
nation
analysi
center
iron
steel
nitric
acid
gr
grade
purchas
damao
chemic
co
ltd
tianjin
china
ultrapur
water
prepar
pass
deioniz
water
milliq
water
system
millipor
billerica
case
water
purifi
deioniz
minimum
conduct
valu
analyt
grade
chemic
obtain
chemic
co
china
anim
maintain
experi
conduct
accord
institut
anim
care
use
committe
jilin
univers
recommend
guid
care
use
laboratori
anim
nation
institut
health
studi
approv
anim
care
use
committe
jilin
univers
permit
number
effort
made
minim
suffer
use
anesthesia
analgesia
postinjuri
care
monitor
male
femal
healthi
wistar
rat
weight
g
purchas
laboratori
anim
center
jilin
univers
china
rat
hous
specif
pathogenfre
facil
control
temperatur
rel
humid
lightdark
cycl
pm
anim
acclim
one
week
laboratori
anim
center
school
public
health
jilin
univers
experiment
procedur
anim
free
access
water
standard
rat
diet
food
withdrawn
night
experi
howev
water
allow
ad
libitum
free
access
food
resum
h
dose
oral
administr
rat
group
randomli
three
group
n
per
group
base
gender
bodi
weight
bw
compound
oral
administ
three
group
rat
singl
dose
mgkg
bw
mlkg
bw
blood
sampl
ml
collect
heparin
tube
h
via
retrobulbar
veniplex
dose
blood
volum
withdrawn
time
point
replac
equal
volum
salin
administ
oral
compens
fluid
loss
blood
sampl
immedi
centrifug
rpm
min
plasma
frozen
analysi
intraven
administr
six
rat
three
male
three
femal
given
compound
singl
dose
mgkg
bw
mlkg
bw
via
caudal
vein
inject
blood
sampl
ml
collect
heparin
tube
h
via
retrobulbar
veniplex
dose
blood
volum
withdrawn
time
point
replac
equal
volum
salin
administ
oral
compens
fluid
loss
blood
sampl
immedi
centrifug
rpm
min
plasma
frozen
analysi
wistar
rat
n
male
femal
equal
oral
given
compound
singl
dose
mgkg
bw
five
rat
durat
h
postdos
sacrif
decapit
administr
compound
whole
brain
heart
liver
spleen
lung
kidney
uteru
testi
ovari
epididymi
stomach
intestin
pancrea
thymu
fat
skelet
muscl
rapidli
dissect
harvest
tissu
organ
weigh
analyt
balanc
frozen
analysi
urin
fece
excret
wistar
rat
n
male
femal
equal
oral
given
compound
singl
dose
mgkg
bw
rat
place
metabol
cage
experi
facilit
urin
fece
collect
urin
fece
collect
h
h
urin
volum
fece
weight
measur
sampl
frozen
analysi
bile
excret
rat
n
male
femal
equal
anesthet
diethyl
ether
bile
duct
cannul
polyethylen
tube
recoveri
anesthesia
rate
oral
administ
compound
dose
mgkg
bw
bile
sampl
collect
h
bile
duct
cannul
bile
volum
measur
sampl
frozen
analysi
variou
amount
compound
ad
pool
male
rat
serum
yield
concentr
mgml
dialysi
membran
spectrapor
ii
beij
dingguo
changsheng
biotechnolog
co
ltd
china
molecular
weight
cutoff
preliminari
studi
demonstr
adsorpt
compound
dialysi
membran
serum
ml
dialyz
ml
moll
isoton
sodium
phosphat
buffer
ph
shake
water
bath
h
shown
necessari
time
equilibr
dialyz
serum
buffer
volum
collect
frozen
analysi
bind
data
correct
fluid
shift
occur
dialysi
experi
done
six
parallel
sampl
follow
formula
use
calcul
plasma
protein
bind
rate
compound
differ
concentr
cplasma
concentr
compound
cbuffer
concentr
compound
buffer
rapid
induct
coupl
plasmamass
spectrometri
icpm
method
establish
determin
concentr
w
nb
sciex
elan
drce
icpm
system
perkinelm
co
usa
use
instrument
paramet
follow
sampl
uptak
rate
mlmin
plasma
ga
flow
rate
lmin
nebul
ga
flow
rate
lmin
auxiliari
ga
flow
rate
lmin
rf
power
w
puls
stage
voltag
v
scan
mode
peak
hop
number
sweep
per
read
dwell
time
sampl
flush
time
sweep
time
wash
time
aliquot
ml
plasma
transfer
test
tube
ml
concentr
ad
test
tube
laid
hot
plate
heat
reflux
h
thorough
dissolut
cool
test
tube
dilut
ultra
pure
water
made
final
volum
ml
analyt
urin
bile
postdialysi
serum
buffer
sampl
aliquot
ml
treat
way
plasma
sampl
tissu
sampl
except
fat
pancrea
aliquot
g
dip
ml
concentr
test
tube
test
tube
laid
hot
plate
heat
reflux
h
thorough
dissolut
cool
test
tube
dilut
ultra
pure
water
made
final
volum
ml
analyt
fece
fat
pancrea
sampl
aliquot
g
dip
ml
concentr
test
tube
test
tube
laid
hot
plate
heat
reflux
h
ml
concentr
ad
h
thorough
dissolut
cool
test
tube
dilut
ultra
pure
water
made
final
volum
ml
analyt
concentr
compound
determin
atom
spectrometri
sampl
analyz
directli
icpm
polyoxometal
concentr
estim
directli
measur
tungsten
concentr
thu
analyt
method
differenti
parent
compound
potenti
degrad
biotransform
product
quantiz
base
mean
n
count
tungsten
calibr
curv
linear
regress
analysi
profil
seri
standard
tungsten
solut
differ
concentr
stock
standard
solut
analyt
w
prepar
separ
dissolv
accur
weigh
standard
substanc
naoh
hf
concentr
store
seri
w
standard
work
solut
ngml
prepar
dilut
stock
solut
appropri
amount
ultra
pure
water
work
solut
freshli
prepar
everi
week
store
qualiti
control
qc
sampl
low
medium
high
concentr
level
ngml
prepar
manner
set
qc
sampl
use
assess
precis
accuraci
recoveri
limit
detect
lod
limit
quantif
loq
lod
loq
determin
lowest
concentr
detect
signal
time
time
higher
baselin
nois
blank
sampl
respect
precis
accuraci
method
evalu
use
qualiti
control
qc
sampl
six
replic
three
concentr
ngml
consecut
day
two
standard
calibr
curv
analyt
run
precis
accuraci
express
rel
standard
deviat
rsd
rel
error
respect
recoveri
proper
volum
qc
sampl
spike
blank
plasma
tissu
urin
fece
render
solut
test
ngml
experi
done
six
parallel
sampl
prepar
detect
calcul
compar
concentr
detect
one
known
advanc
recoveri
calcul
formula
cm
concentr
measur
cb
blank
concentr
cp
concentr
prepar
analyt
method
use
studi
necessarili
specif
rather
estim
polyoxometal
concentr
reflect
concentr
metal
w
atom
thu
pharmacokinet
analysi
describ
overal
disposit
parent
polyoxometal
possibl
degrad
metabol
product
well
pharmacokinet
analysi
perform
use
kinet
comput
softwar
thermo
scientif
inc
usa
result
express
deriv
sd
data
subject
oneway
analysi
varianc
anova
follow
least
signific
differ
lsd
posthoc
test
differ
consid
statist
signific
p
linear
correl
done
evalu
relationship
dose
paramet
differ
consid
statist
signific
p
statist
analys
perform
spss
softwar
packag
spss
inc
usa
specif
icpm
use
special
interfac
techniqu
incorpor
induct
coupl
plasma
quadrupol
mass
spectrum
involv
high
temperatur
k
ioniz
sourc
sensit
rapid
scan
mass
detector
compar
tradit
element
analysi
method
graphit
furnac
atom
absorpt
spectrometri
gfaa
induct
coupl
plasma
atom
emiss
spectrometri
icpa
icpm
provid
improv
sensit
select
suitabl
pharmacokinet
studi
addit
icpm
satisfi
detect
requir
inorgan
element
analysi
limit
detect
achiev
level
sub
ppt
also
abil
determin
mani
element
time
lod
loq
concentr
w
blank
plasma
sampl
detect
lod
loq
indic
sensit
assay
found
ngml
respect
standard
curv
linear
rang
calibr
curv
linear
regress
correl
coeffici
r
curv
equat
correl
coeffici
plasma
tissu
urin
fece
bile
follow
plasma
r
liver
r
fat
r
skelet
muscl
r
urin
r
fece
r
bile
r
linear
rang
ngml
precis
accuraci
intraday
interday
precis
express
rsd
accuraci
express
assay
shown
tabl
intra
interday
precis
accuraci
within
accept
limit
ie
less
rsd
low
qc
medium
qc
high
qc
sampl
overal
intraday
accuraci
precis
assay
rang
respect
correspond
valu
interday
run
similar
give
precis
recoveri
result
recoveri
shown
tabl
mean
recoveri
rat
plasma
tissu
urin
fece
bile
low
middl
high
qc
sampl
approxim
demonstr
recoveri
high
plasma
concentrationtim
profil
compound
intraven
administr
character
rat
illustr
figur
data
fit
conduct
result
show
pharmacokinet
behavior
compound
fit
two
compart
model
main
pharmacokinet
paramet
compound
summar
tabl
pharmacokinet
profil
compound
investig
wistar
rat
singl
oral
dose
mgkg
mean
plasma
curv
compound
present
fig
pharmacokinet
paramet
list
tabl
data
fit
conduct
result
show
pharmacokinet
behavior
compound
fit
two
compart
model
except
cmax
signific
differ
p
observ
pharmacokinet
paramet
among
three
differ
group
cmax
linear
correl
dose
p
absolut
bioavail
dosecorrect
area
curv
auc
oral
divid
auc
intraven
formula
calcul
f
drug
administ
oral
rout
po
given
assay
absolut
bioavail
compound
mgkg
group
respect
tissu
distribut
compound
oral
administr
mgkg
present
figur
highest
deposit
found
kidney
follow
stomach
intestin
liver
less
deposit
found
brain
result
show
major
organ
deposit
compound
kidney
accumul
excret
rate
urin
fece
bile
illustr
figur
result
indic
main
excret
mechan
compound
fece
account
drug
test
urin
account
approxim
bile
account
till
h
compound
excret
total
amount
administr
till
h
compound
excret
total
amount
administr
result
also
indic
compound
easili
accumul
vivo
rat
plasma
bind
rate
compound
shown
tabl
percentag
compound
bound
mgml
respect
indic
compound
highli
bound
rat
plasma
protein
mgml
treatment
patient
chronic
hbv
infect
remain
critic
clinic
problem
polyoxometal
nonnucleosid
analog
proven
exhibit
broad
inhibitori
activ
herp
simplex
viru
influenza
viru
sar
viru
previou
studi
treatment
cell
compound
effect
suppress
secret
hbv
antigen
hbv
dna
therefor
pharmacokinet
studi
compound
critic
fight
viral
atntigen
pharmacokinet
profil
compound
rat
determin
quantit
icpm
method
demonstr
good
sensit
accuraci
precis
recoveri
pharmacokinet
behavior
compound
intraven
oral
administr
fit
two
compart
model
cmax
linear
correl
oral
dose
p
howev
ke
cl
mrt
vd
chang
increas
administ
dose
indic
pharmacokinet
characterist
compound
compli
linear
dynam
compound
abl
absorb
quickli
blood
circul
system
intraven
oral
administr
rat
tmax
rang
h
h
halflif
compound
h
h
show
good
prospect
compound
longtimeus
drug
treatment
chronic
hepat
assay
absolut
bioavail
compound
mgkg
respect
indic
oral
bioavail
compound
rat
low
studi
absorpt
elimin
also
necessari
oral
administr
mgkg
compound
compound
distribut
test
tissu
highest
deposit
h
found
stomach
intestin
concentr
decreas
time
pass
indic
main
rout
absorpt
gastrointestin
tract
addit
gastrointestin
tract
compound
also
deposit
liver
kidney
lung
spleen
blood
flow
contrast
compound
deposit
less
fat
skelet
muscl
littl
blood
low
concentr
compound
testi
epididymi
ovari
uteru
consist
result
reproduct
toxic
experi
found
obviou
reproduct
toxic
compound
much
lower
content
heart
suggest
cardiovascular
system
prone
impair
compound
less
deposit
found
brain
suggest
compound
go
blood
brain
barrier
easili
content
compound
kidney
liver
high
time
content
tissu
impli
kidney
liver
main
metabol
elimin
posit
may
possibl
toxic
site
high
content
liver
also
favor
treatment
chronic
hepat
clearanc
tissu
rather
quick
content
tissu
less
peak
content
h
percentag
bound
compound
mgml
respect
indic
compound
highli
bound
rat
plasma
protein
mgml
moder
bound
mgml
result
indic
compound
exist
combin
form
plasma
protein
system
circul
howev
bind
forc
may
weak
therefor
like
outcompet
highbind
drug
accumul
excret
result
indic
main
rout
excret
compound
fece
contain
drug
test
urin
contain
bile
contain
h
approxim
total
amount
administ
compound
excret
result
also
indic
compound
easili
accumul
vivo
studi
compound
metabolit
excret
also
essenti
summari
quantit
icpm
method
establish
demonstr
good
sensit
applic
pharmacokinet
studi
polyoxometal
pharmacokinet
behavior
compound
intraven
oral
administr
fit
two
compart
model
compound
highli
bound
plasma
protein
compound
wide
distribut
throughout
bodi
high
level
compound
found
kidney
liver
excret
compound
lower
urin
fece
bile
preclin
pharmacokinet
studi
show
compound
appear
properti
result
could
provid
refer
studi
metabol
compound
conclus
investig
pharmacokinet
compound
possess
inhibitori
hbv
data
laid
good
foundat
develop
pom
attract
antihbv
drug
